45 Results for "

Fc+region

" in MedChemExpress (MCE) Product Catalog:
Products (45)

45 Results for "Fc+region" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-108801A
CAS No.: 862111-32-8
Purity:  97.66%

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Cancer

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108801
CAS No.: 862111-32-8
Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

Target:  

VEGFR

Aflibercept is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-NP006
CAS No.: 308083-69-4
Synonyms: SPA
Protein A (SPA) is an immunoglobulin (Ig)-binding protein that exists on the bacterial surface and can be freely secreted into the extracellular environment. Protein A blocks opsonophagocytosis and induces B cell apoptosis in vitro by binding to the Fc region of antibodies and the Fab region of B cell receptors. Protein A can form toxic immune complexes with IgG, thereby inducing leukocyte necrosis. Protein A contributes to the virulence expression of Staphylococcus aureus. Protein A triggers allergic reactions in IgG-pretreated mouse models. Protein A can be used in studies related to immune system diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99777
CAS No.: 2131089-46-6
Synonyms: TTI-621

Target:  

CD47

Research Areas:  

Cancer

Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99395
CAS No.: 1826831-79-1
Synonyms: JNJ 56022473; CSL 362

Target:  

Interleukin Related

Research Areas:  

Cancer

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
loading...
    loading...
Cat. No.: HY-P9954
CAS No.: 509077-98-9

Target:  

CD3

Research Areas:  

Cancer

Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
loading...
    loading...
Cat. No.: HY-P99950
CAS No.: 2484949-51-9
Synonyms: ALX148

Target:  

CD47

Research Areas:  

Cancer

Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-P990735
CAS No.: 2765066-99-5
Synonyms: UCB-1381

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G4S)2 linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions .
loading...
    loading...
Cat. No.: HY-P99674
CAS No.: 2364496-42-2
Synonyms: GEN-3009

Research Areas:  

Cancer

Ivicentamab (GEN-3009) is a bispecific antibody targeting CD37 with dual epitopes. Ivicentamab carries an E430G mutation in the Fc region, which efficiently promotes IgG hexamer formation on the surface of target cells. Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody, enabling it to exert complement-dependent cytotoxicity in Daudi lymphoma cells. Ivicentamab is mainly used in lymphoma-related research .
loading...
    loading...
Cat. No.: HY-E70884
Synonyms: EndoS2 D184M
Target:  

Glycosidase

Research Areas:  

Others

Endoglycosidase S2 (D184M mutant) (EndoS2 D184M) is a mutant endoglycosidase. Endoglycosidase S2 (D184M mutant) promotes the transfer of glyco-oxazoline donors with defined glycoforms to the Fc region of IgG antibodies .
loading...
    loading...
Cat. No.: HY-P990707
CAS No.: 2631667-06-4
Synonyms: TTI-622; PF-07901801

Target:  

CD47

Research Areas:  

Inflammation/Immunology

Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
loading...
    loading...
Cat. No.: HY-P990941
CAS No.: 2853518-94-0
Synonyms: F131; GEN1184 antibody

Target:  

Antifolate

Research Areas:  

Inflammation/Immunology

Rinatabart (F131) is an IgG1-κ human antibody targeting FOLR1, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001). The Fc region of Rinatabart is engineered to reduce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. The KD values of Rinatabart binding to human FOLR1 in two sets of BLI assays are 1.528 nM and 5.296 nM, respectively. Rinatabart shows significantly lower affinity for FOLR2 and mouse FOLR1, and no reliable specific binding to FOLR3 and rat FOLR1. Rinatabart can be used in studies of FOLR1 targeting and antibody-drug conjugates .
loading...
    loading...
Cat. No.: HY-P991582

Research Areas:  

Cancer

BI-1607 is a humanized monoclonal antibody targeting FcγRIIB/CD32b. BI-1607 selectively blocks inhibitory FcγRIIB signaling, abrogates its inhibitory function, redirects tumor cell-bound antibodies to activating FcγRs, and its modified Fc region prevents the binding of its own Fc segment to FcγRs. BI-1607 reduces αPD-1 trogocytosis, enhances the effector functions of anti-tumor antibodies (including ADCP and ADCC, promotes intratumoral regulatory T cell (Treg) depletion, myeloid cell reprogramming, induction of interferon-γ (IFN-γ) and CXCL10, and increases the number of activated effector CD8 + T cells. BI-1607 can be used in research related to colorectal cancer, HER2-positive advanced solid tumors, HER2-positive locally advanced or metastatic breast cancer, and HER2-positive metastatic gastric cancer .
loading...
    loading...
Cat. No.: HY-P2665
CAS No.: 120484-65-3
Target:  

Peptides

Research Areas:  

Others

Lymphocyte activating pentapeptide is a short peptide sequence found in the Fc region of human IgG1 that has the ability to activate lymphocytes. Lymphocyte activating pentapeptide can be used to study the activation mechanisms of B cells and T cells, and their role in immune responses .
loading...
    loading...
Cat. No.: HY-P10544
CAS No.: 223744-37-4
Target:  

Interleukin Related

Research Areas:  

Others

Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .
loading...
    loading...
Cat. No.: HY-P990231

Target:  

Inhibitory Antibodies

Research Areas:  

Others

Anti-Rat IgG1 Antibody (RG11/39.4) is a mouse-derived IgG2c κ type antibody inhibitor, targeting to rat IgG1. Anti-Rat IgG1 Antibody (RG11/39.4) reacts with the Fc region of rat IgG1. Anti-Rat IgG1 Antibody (RG11/39.4) can be used for detection of flow cytometry .
loading...
    loading...
Cat. No.: HY-P990230

Target:  

Inhibitory Antibodies

Research Areas:  

Others

Anti-Rat IgG2a Antibody (RG7/1.30) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to rat IgG2a. Anti-Rat IgG2a Antibody (RG7/1.30) reacts with the Fc region of rat IgG2a. Anti-Rat IgG2a Antibody (RG7/1.30) can be used for detections of immunofluorescence, flow cytometry and ELISA .
loading...
    loading...
Cat. No.: HY-P10492
Target:  

Peptides

Research Areas:  

Others Metabolic Disease

Tregitope 289 is a peptide derived from the Fc region of immunoglobulin G (IgG) and is a highly conserved T cell epitope that stimulates the expansion of natural regulatory T cells. Co-delivery of Tregitope 289 with type 1 diabetes (T1D) antigens delays the development of hyperglycemia and reduces the incidence of diabetes in the NOD mouse model. Tregitope 289 can be used to study T1D and other autoimmune diseases .
loading...
    loading...
Cat. No.: HY-P991997

Target:  

Fc Receptor (FcR)

Research Areas:  

Others

Anti-CD16a Antibody (3G8) is a pan-CD16-specific antibody. Anti-CD16a Antibody (3G8) binds to an epitope overlapping with CD16a’s Fc binding site, inhibiting CD16a-IgG Fc region interactions.Anti-CD16a Antibody (3G8) recognizes CD16a, CD16b, and CD16b-NA1 and NA2 allelotypes expressed by neutrophils .
loading...
    loading...
Cat. No.: HY-P992381

Target:  

Drug Derivative

Research Areas:  

Cancer

IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
loading...
    loading...